EcoDrugPlus

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSBBBG00000013740
Gene Symbol: HTR5A
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSBBBG00000016201
Gene Symbol: HTR6
3 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSBBBG00000015945
Gene Symbol: HTR7
1 Cross references
221 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSBBBG00000023690
Gene Symbol: LOC104993455
2 Cross references
73 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSBBBG00000019417
Gene Symbol: LOC104983708
2 Cross references
115 Possible Orthologues:

60s Ribosomal Protein L39

Ensembl ID : ENSBBBG00000006656
Gene Symbol: LOC104990758
2 Cross references
68 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSBBBG00000009543
Gene Symbol: ABL1
3 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSBBBG00000002244
Gene Symbol: ADAM17
3 Cross references
283 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSBBBG00000002551
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSBBBG00000023624
Gene Symbol: ADRM1
3 Cross references
261 Possible Orthologues:

Akt Serine/threonine Kinase 2

Ensembl ID : ENSBBBG00000018063
Gene Symbol: AKT2
3 Cross references
257 Possible Orthologues:

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSBBBG00000001065
Gene Symbol: ALK
3 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).